BioHarvest Sciences

BHST

Market cap $217M

BioHarvest Sciences Inc. (NASDAQ:BHST) has strengthened its finances by pulling in $10.9 million in fresh investment and trimming $3.8 million in debt through a series of deals involving warrants and convertible notes. The biotechnology company said Monday the transactions leave it with total debt of about $6.6 million, split between $3.6 million in short-term borrowings and $3 million in long-term obligations.

Rehovot, Israel--(Newsfile Corp. - September 22, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) ("BioHarvest" or the "Company"), a biotechnology company pioneering its patented Botanical Synthesis technology platform, today announced the successful completion of a series of accelerated warrant exercises and conversions of debt to equity, which fortifies the Company's balance sheet with an additional $10.9 Million in gross proceeds and a concurrent $3.8 Million reduction in total debt. The following are the transactions which were executed subsequent to the Company's published Q2 2025 Financial Statements: Successfully raised $5.8 Million in incremental cash through the exercising of 898,277 warrants; Raised an additional $5.1 Million proceeds from the issuance of new Convertible Notes to multiple accredited investors that were subsequently converted into common shares; Converted $1.8 Million of pre-existing Convertible Notes into common shares; Repaid $1.4 Million of Long-Term Debt following lenders exercising 214,915 warrants; and Repaid $0.6 Million of Short-Term Debt via the issuance of shares The series of transactions were designed to deleverage the balance sheet and provide additional cash runway in support of the Company's continued growth.

BioHarvest Sciences Inc. (NASDAQ:BHST ) Virtual Investor Webinar Conference September 10, 2025 01:00 PM ET Company Participants Ilan Sobel - Chief Executive Officer Zaki Rakib - Co-Founder, Executive Chairman & President Conference Call Participants Nicholas Sherwood - Maxim Group LLC, Research Division Hunter Diamond - Diamond Equity Research LLC Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Alec Legg - Canaccord Genuity Corp., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Good day, and welcome to the BioHarvest Sciences Virtual Investor Webinar. Today's webinar is being recorded.

BioHarvest Sciences Inc. (NASDAQ:BHST) announced it has successfully produced plant-based exosomes at scale in its proprietary bioreactors, a development the company says represents a breakthrough in its Botanical Synthesis platform. Exosomes are nano-sized extracellular vesicles secreted by plant cells that carry bioactive compounds with higher absorption and bioavailability compared to standard plant-derived molecules, the company said on Wednesday.

Exosomes Produced in the Liquid Media of the BioHarvest Unique Large-Scale Bioreactors Add Potential New Revenue Stream from Products and CDMO Opportunities Rehovot, Israel--(Newsfile Corp. - September 10, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it has successfully produced, at scale, plant-based exosomes in its bioreactor media, marking a significant advancement in the Company's proprietary Botanical Synthesis platform and in its ability to generate new revenue streams. Exosomes are nano-sized extracellular vesicles naturally secreted by plant cells, with bioactive properties with enhanced absorption and bioavailability levels versus regular plant compounds.

Rehovot, Israel--(Newsfile Corp. - September 2, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management will host a Virtual Investor Webinar on Wednesday, September 10, 2025 at 1:00 p.m. Eastern time.

BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.04 per share a year ago.

BioHarvest Sciences Inc. (NASDAQ:BHST ) Q2 2025 Earnings Conference Call August 11, 2025 8:00 AM ET Company Participants Bar Dichter - Chief Financial Officer Ilan Sobel - Chief Executive Officer Conference Call Participants Amit Dayal - H.C. Wainwright & Co, LLC, Research Division Anthony V.

BioHarvest Sciences Inc. (NASDAQ:BHST) reported a 41% rise in second-quarter revenue, driven by growth in its VINIA product line and contributions from its contract development and manufacturing (CDMO) business. Revenue for the quarter ended June 30 rose to $8.5 million from $6 million a year earlier, in line with the company's guidance.

Robust 41% Year-Over-Year Revenue Growth, Driven by Strong Core Capsule and New Product Sales Rehovot, Israel--(Newsfile Corp. - August 11, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today reported its financial and operational results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights All figures stated in this news release are in U.S. dollars unless stated otherwise.